Top Abstract Purchase Related
Home
>
Node
>
Subnode

Cyclic adenosine monophoshate phosphodiesterase: a possible marker of thyroid pathology?

Spoto, G.; D'Alessandro, L.; Rubini, C.; Fioroni, M.; Rutjes, A.W.S.; Spoto, S.; Ferrante, M.; Della Malva, M.; Petrini, M.

Journal of Biological Regulators and Homeostatic Agents 33(1): 281-285

2019

ISSN/ISBN: 0393-974X
PMID: 30697984
Document Number: 699313
The aim of this study was to evaluate whether or not the expression of cAMP-phosphodiesterases (cAMP-PDE) varies in different thyroid pathologies and to elucidate the relationship between the expression of cAMP-PDE and clinic-pathologic factors. Forty thyroid biopsy samples, excised to perform the biopsy, were microscopically examined and classified. Then cAMP-PDE expression was assessed using high performance liquid chromatography. The expression of cAMP-PDE showed different patterns according to the histological features of the samples (p less than 0.001). A strong expression of cAMP-PDE was observed more frequently in papillar and follicular carcinoma than in controls and benign pathologies. We did not detect any level of endogenous cAMP. cAMP could be used as additional diagnostic or prognostic biomarker in patients suspected of thyroid disease, however further studies are needed to confirm these results.

Document emailed within 1 workday
Secure & encrypted payments

Kozhemiakin, L.A.; Korostovtsev, D.S.; Koroleva, T.R. 1978: Antihypoxic effect of analogs of cyclic adenosine monophosphate, phosphodiesterase inhibitors Farmakologiia i Toksikologiia 41(6): 711-714
Gräfe, U.; Römer, W. 1991: 2-Aza-anthraquinones as inhibitors of the Ca(2+)- and calmodulin-dependent cyclic adenosine 3',5'-monophosphate phosphodiesterase Die Pharmazie 46(4): 297-298
Scholz, P.M.; Jolley, W.B.; Novinson, T.C.; Kaiser, J.E.; Smith, L.L. 1972: Influence of altered cyclic 3',5'-adenosine monophosphate phosphodiesterase activity on systemic hemodynamics Surgical Forum 23(0): 189-191
Scher, N.S.; Quagliata, F.; Malathi, V.G.; Faig, D.; Melton, R.A.; Silber, R. 1976: Cyclic adenosine 3':5'-monophosphate phosphodiesterase activity in normal and chronic lymphocytic leukemia lymphocytes Cancer Research 36(11 Part 1): 3958-3962
Hickie, R.A.; Walker, C.M.; Datta, A. 1975: Increased activity of low-Km cyclic adenosine 3':5'-monophosphate phosphodiesterase in plasma membranes of Morris hepatoma 5123tc (h) Cancer Research 35(3): 601-605
Mufson, R.A.; Simsiman, R.C.; Boutwell, R.K. 1979: Increased cyclic adenosine 3':5'-monophosphate phosphodiesterase activity in the epidermis of phorbol ester-treated mouse skin and in papillomas Cancer Research 39(6 Part 1): 2036-2040
Erneux, C.; Couchie, D. 1979: Characterization of various horse thyroid forms of cyclic-nucleotide phosphodiesterase Archives Internationales de Physiologie et de Biochimie 87(2): 408-410
Zahavi, M.; Zahavi, J.; Kakkar, V.V. 1984: Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation Thrombosis and Haemostasis 52(2): 205-209
Prashad, N.; Rosenberg, R.; Baskin, F.; Sparkman, D.; Ulrich, C.; Wischmeyer, B. 1980: Cyclic adenosine 3':5'-monophosphate-binding protein, a biochemical marker of neuroblastoma differentiation Cancer Research 40(8 Part 1): 2884-2889
Ozeredenko, V.G.; Fedorova, L.P.; Mikhaĭlova, E.I. 1990: Plasma levels of cyclic nucleotides, phosphodiesterase, thyroid hormones and insulin in patients with ischemic stroke Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova 90(7): 25-26
Nicholson, C.D.; Shahid, M.; Bruin, J.; Barron, E.; Spiers, I.; de Boer, J.; van Amsterdam, R.G.; Zaagsma, J.; Kelly, J.J.; Dent, G. 1995: Characterization of ORG 20241, a combined phosphodiesterase IV/IIi cyclic nucleotide phosphodiesterase inhibitor for asthma Journal of Pharmacology and Experimental Therapeutics 274(2): 678-687
Kofinas, A.D.; Rose, J.C.; Koritnik, D.R.; Meis, P.J. 1990: Progesterone and estradiol concentrations in nonpregnant and pregnant human myometrium. Effect of progesterone and estradiol on cyclic adenosine monophosphate-phosphodiesterase activity Journal of Reproductive Medicine 35(11): 1045-1050
Yamasaki, Y.; Fujiwara, M.; Toda, N. 1974: Effects of intracellularly applied cyclic 3',5'-adenosine monophosphate and dibutyryl cyclic 3',5'-adenosine monophosphate on the electrical activity of sinoatrial nodal cells of the rabbit Journal of Pharmacology and Experimental Therapeutics 190(1): 15-20
Gintzler, A.R.; Musacchio, J.M. 1975: Interactions of morphine, adenosine, adenosine triphosphate and phosphodiesterase inhibitors on the field-stimulated guinea-pig ileum Journal of Pharmacology and Experimental Therapeutics 194(3): 575-582
Turakulov, I.K.; Atakhanova, B.A.; Kadyrova, D.A. 1975: Stimulation of the protein synthesizing capacity of thyroid gland polyribosomes in vitro under the influence of cyclic adenosine-3', 5'-monophosphate Problemy Endokrinologii 21(2): 82-85
Silver, P.J.; Lepore, R.E.; O'Connor, B.; Lemp, B.M.; Hamel, L.T.; Bentley, R.G.; Harris, A.L. 1988: Inhibition of the low Km cyclic AMP phosphodiesterase and activation of the cyclic AMP system in vascular smooth muscle by milrinone Journal of Pharmacology and Experimental Therapeutics 247(1): 34-42
Nakano, J.; Ishii, T. 1970: Effect of ketone bodies on hormone-, theophylline- and dibutryl cyclic AMP-induced lipolysis and on cyclic AMP-phosphodiesterase Research Communications in Chemical Pathology and Pharmacology 1(4): 485-496
Walseth, T.F.; Yuen, P.S.; Moos, M.C. 1991: Preparation of alpha-32P-labeled nucleoside triphosphates, nicotinamide adenine dinucleotide, and cyclic nucleotides for use in determining adenylyl and guanylyl cyclases and cyclic nucleotide phosphodiesterase Methods in Enzymology 195: 29-44
Cheung, W.Y. 1970: Cyclic nucleotide phosphodiesterase Advances in Biochemical Psychopharmacology 3: 51-65
Nedvídková, J.; Felt, V. 1984: Plasma levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in patients with thyropathies Casopis Lekaru Ceskych 123(27): 835-837